Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Life Sciences	$1.39 -0.7%	$1.42	$1.03 ▼ $2.57	$277.72M	1.22	1.52 million shs	1.08 million shs
AURA Aura Biosciences	$5.23 -9.8%	$6.12	$4.84 ▼ $12.38	$262.68M	0.43	205,960 shs	227,320 shs
FULC Fulcrum Therapeutics	$5.37 -0.7%	$3.38	$2.32 ▼ $10.13	$289.87M	2.29	973,552 shs	537,283 shs
JSPR Jasper Therapeutics	$4.52 +2.0%	$4.66	$3.13 ▼ $26.84	$67.90M	2.74	290,779 shs	129,296 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Life Sciences	-0.36%	-7.33%	+6.92%	-36.24%	-30.85%
AURA Aura Biosciences	-9.83%	-14.96%	-2.43%	-32.95%	-29.23%
FULC Fulcrum Therapeutics	-0.74%	-4.45%	+86.46%	+45.53%	-29.25%
JSPR Jasper Therapeutics	+2.73%	-16.45%	+24.86%	-26.38%	-78.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI Atai Life Sciences	3.0154 of 5 stars	3.5	1.0	3.3	3.3	1.3
AURA Aura Biosciences	2.351 of 5 stars	3.6	2.0	2.8	2.5	0.0
FULC Fulcrum Therapeutics	1.9927 of 5 stars	3.1	2.0	3.2	2.5	0.0
JSPR Jasper Therapeutics	2.3488 of 5 stars	3.5	2.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Life Sciences	3.00	Buy	$10.50	655.40% Upside
AURA Aura Biosciences	3.25	Buy	$22.75	334.99% Upside
FULC Fulcrum Therapeutics	2.11	Hold	$8.63	60.61% Upside
JSPR Jasper Therapeutics	3.00	Buy	$62.50	1,282.74% Upside

Current Analyst Ratings Breakdown

Latest JSPR, FULC, AURA, and ATAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/26/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$19.00
3/26/2025	AURA Aura Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
3/25/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$25.00
3/24/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
3/19/2025	ATAI Atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/11/2025	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
2/26/2025	FULC Fulcrum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00
2/13/2025	ATAI Atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
2/13/2025	JSPR Jasper Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$38.00

(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Life Sciences	$308K	901.67	N/A	N/A	$1.47 per share	0.95
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$4.58 per share	N/A
FULC Fulcrum Therapeutics	$80M	3.62	N/A	N/A	$3.80 per share	1.41
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$7.03 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Life Sciences	-$40.22M	-$0.93	N/A	N/A	N/A	N/A	-65.75%	-52.71%	5/13/2025 (Estimated)
AURA Aura Biosciences	-$76.41M	-$1.75	N/A	N/A	N/A	N/A	-41.57%	-36.43%	N/A
FULC Fulcrum Therapeutics	-$97.33M	-$0.07	N/A	N/A	N/A	N/A	-7.31%	-6.74%	5/12/2025 (Estimated)
JSPR Jasper Therapeutics	-$64.46M	-$4.86	N/A	N/A	N/A	N/A	-67.64%	-58.53%	5/13/2025 (Estimated)

Latest JSPR, FULC, AURA, and ATAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	ATAI Atai Life Sciences	-$0.19	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	JSPR Jasper Therapeutics	-$1.17	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A
3/24/2025	Q4 2024	AURA Aura Biosciences	-$0.43	-$0.52	-$0.09	-$0.52	N/A	N/A
3/17/2025	Q4 2024	ATAI Atai Life Sciences	-$0.14	-$0.24	-$0.10	-$0.24	$0.30 million	($0.01) million
2/27/2025	Q4 2024	JSPR Jasper Therapeutics	-$1.27	-$1.62	-$0.35	-$1.62	N/A	N/A
2/25/2025	Q4 2024	FULC Fulcrum Therapeutics	-$0.28	-$0.31	-$0.03	-$0.31	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Life Sciences	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Life Sciences	0.14	5.81	5.81
AURA Aura Biosciences	N/A	12.47	12.47
FULC Fulcrum Therapeutics	N/A	18.44	18.44
JSPR Jasper Therapeutics	N/A	7.61	7.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Life Sciences	28.41%
AURA Aura Biosciences	96.75%
FULC Fulcrum Therapeutics	89.83%
JSPR Jasper Therapeutics	79.85%

Insider Ownership

Company	Insider Ownership
ATAI Atai Life Sciences	31.20%
AURA Aura Biosciences	5.40%
FULC Fulcrum Therapeutics	4.10%
JSPR Jasper Therapeutics	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Life Sciences	80	199.80 million	115.45 million	Optionable
AURA Aura Biosciences	50	50.23 million	47.25 million	Not Optionable
FULC Fulcrum Therapeutics	100	53.98 million	51.73 million	Optionable
JSPR Jasper Therapeutics	20	15.02 million	14.60 million	Optionable

JSPR, FULC, AURA, and ATAI Headlines

Recent News About These Companies

Jasper Therapeutics (JSPR) Expected to Announce Earnings on Tuesday

May 8 at 11:21 AM | marketbeat.com

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Acquired by Braidwell LP

May 8 at 6:30 AM | marketbeat.com

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Recommendation of "Buy" from Analysts

May 8 at 4:23 AM | marketbeat.com

Why Jasper Therapeutics, Inc.’s (JSPR) Stock Is Down 5.34%

May 6, 2025 | aaii.com

Ally Bridge Group NY LLC Decreases Stock Holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

May 4, 2025 | marketbeat.com

Boxer Capital Management LLC Buys New Shares in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

May 4, 2025 | marketbeat.com

T. Rowe Price Investment Management Inc. Makes New $1.76 Million Investment in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

April 30, 2025 | marketbeat.com

Why Jasper Therapeutics, Inc.’s (JSPR) Stock Is Up 7.05%

April 22, 2025 | aaii.com

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of "Buy" from Analysts

April 13, 2025 | marketbeat.com

Why Jasper Therapeutics, Inc.’s (JSPR) Stock Is Up 7.55%

April 11, 2025 | aaii.com

Jasper Therapeutics inks new sales agreement, ends previous deal

March 21, 2025 | uk.investing.com

Jasper Therapeutics files $300M mixed securities shelf

March 19, 2025 | markets.businessinsider.com

Jasper Therapeutics presents updated data from Phase 1b/2a BEACON study

March 2, 2025 | msn.com

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

March 1, 2025 | globenewswire.com

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

February 28, 2025 | globenewswire.com

Jasper Therapeutics Reports Promising Clinical Progress

February 28, 2025 | tipranks.com

Jasper Therapeutics reports Q4 EPS ($1.62), consensus ($1.23)

February 27, 2025 | markets.businessinsider.com

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

February 27, 2025 | globenewswire.com

Jasper Therapeutics to Present at Upcoming March Investor Conferences

February 25, 2025 | globenewswire.com

UBS Initiates Coverage of Jasper Therapeutics (JSPR) with Buy Recommendation

February 14, 2025 | msn.com

Jasper Therapeutics initiated with a Buy at UBS

February 13, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR, FULC, AURA, and ATAI Company Descriptions

Atai Life Sciences NASDAQ:ATAI

$1.39 -0.01 (-0.71%)

As of 05/9/2025 04:00 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Aura Biosciences NASDAQ:AURA

$5.23 -0.57 (-9.83%)

As of 05/9/2025 03:58 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Fulcrum Therapeutics NASDAQ:FULC

$5.37 -0.04 (-0.74%)

As of 05/9/2025 04:00 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Jasper Therapeutics NASDAQ:JSPR

$4.52 +0.09 (+2.03%)

As of 05/9/2025 04:00 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time